$TRUMP Daiichi Sankyo's first-half profit rises, supported by growth in cancer drugs
Daiichi Sankyo (TYO:4568) reported stronger financial results for the first half of its fiscal year, supported by strong demand for its cancer treatments and the weak Japanese yen, while the Japanese pharmaceutical company maintained its full-year forecast.
Core operating profit rose 46.9% year over year to 221.3 billion yen ($1.41 billion) in the six months ended 30/09, while revenue grew 19.7% to 1.17 trillion yen, the company announced on Friday.
$XAU
#EarningsSeason #USMidtermElections #BinanceWillListPredictPREDICT #SwitzerlandFirstSpotBitcoinETFExpectedToTradeInNovember #Strategy三季度营业利润210亿美元
Daiichi Sankyo (TYO:4568) reported stronger financial results for the first half of its fiscal year, supported by strong demand for its cancer treatments and the weak Japanese yen, while the Japanese pharmaceutical company maintained its full-year forecast.
Core operating profit rose 46.9% year over year to 221.3 billion yen ($1.41 billion) in the six months ended 30/09, while revenue grew 19.7% to 1.17 trillion yen, the company announced on Friday.
$XAU
#EarningsSeason #USMidtermElections #BinanceWillListPredictPREDICT #SwitzerlandFirstSpotBitcoinETFExpectedToTradeInNovember #Strategy三季度营业利润210亿美元
